Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SNNA - Sienna Biopharmaceuticals Inc.

Previous close
0.1358
0   0%

Share volume: 0
Last Updated: Mon 16 Dec 2019 06:00:00 AM CET
Pharmaceuticals: Major: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$0.14
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 25%
Dept financing 25%
Liquidity 38%
Performance 45%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.14
P/E Ratio 
N/A
DAY RANGE
$0.14 - $0.14
EPS 
-$2.00
52 WEEK RANGE
$0.10 - $0.17
52 WEEK CHANGE
$0.00
MARKET CAP 
4.197 M
YIELD 
N/A
SHARES OUTSTANDING 
30.908 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$22,265,639
AVERAGE 10 VOLUME 
$13,315,740
AVERAGE 30 VOLUME 
$13,315,740
Company detail
CEO: Frederick C. Beddingfield
Region: US
Website: http://www.siennabio.com
Employees: 58
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Major
Sector: Health Technology

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Recent news